Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients
New data presented at EHA23 indicates the potential of gilteritinib in eradicating minimal residual disease and its implications for improving outcomes in high-risk AML patients.